<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7338588\results\search\testTrace\results.xml">
  <result pre="disease-19 (COVID-19) describes a set of symptoms that develop following" exact="infection" post="by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."/>
  <result pre="significant co-morbidities, the reason for healthy individuals succumbing to fulminant" exact="infection" post="is largely unexplained. In this review, we discuss the"/>
  <result pre="IRF9 (17), TLR3 (18), GATA2 (19), and RIG-I (20), rhinovirus" exact="infection" post="and MDA5 (21), papillomaviruses and mutations in EVER1/2 (22),"/>
  <result pre="(24), XIAP (25), ITK (26), and MAGT1 (27), fatal CMV" exact="infection" post="in NOS2 deficiency (28), and finally disseminated infection with"/>
  <result pre="fatal CMV infection in NOS2 deficiency (28), and finally disseminated" exact="infection" post="with measles vaccine strain virus in IFNAR and STAT2"/>
  <result pre="presents with non-specific signs and symptoms of upper airway viral" exact="infection" post="characterized by fever, fatigue, cough, and dyspnoea, as well"/>
  <result pre="developing aneurisms. This inflammatory condition associated with a previous SARS-CoV-2" exact="infection" post="has been named Pediatric Multisystem Inflammatory Syndrome temporally associated"/>
  <result pre="against a wide range of pathogens, particularly viruses. Importantly, viral" exact="infection" post="induces type I interferons (IFN) (IFNÎ±/Î²) and type III"/>
  <result pre="signaling pathways that are known to be activated during viral" exact="infection" post="and replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
  <result pre="by extracellular virus through TLR4. Several studies have demonstrated that" exact="infection" post="of Tlr3âˆ’/âˆ’, Tlr4âˆ’/âˆ’, Trifâˆ’/âˆ’, Tramâˆ’/âˆ’, and Myd88âˆ’/âˆ’ mice with"/>
  <result pre="downstream adaptors TRIF and MyD88 (77, 78). Interestingly, following SARS-CoV" exact="infection" post="of Trifâˆ’/âˆ’ mice, the aberrant proinflammatory cytokine and chemokine"/>
  <result pre="seen in human patients with poor disease outcome during SARS-CoV" exact="infection" post="(80) or MERS-CoV infection (81). This may suggest that"/>
  <result pre="with poor disease outcome during SARS-CoV infection (80) or MERS-CoV" exact="infection" post="(81). This may suggest that the initial impaired control"/>
  <result pre="studies have failed to report increased susceptibility to severe viral" exact="infection" post="in patients deficient in these molecules (82). This underlines"/>
  <result pre="(85). Investigations into the role of lung inflammation during respiratory" exact="infection" post="identified a potential role for excessive inflammasome activation. Mice"/>
  <result pre="been deleted by CASP1/11 knock-out displayed less mortality upon influenza" exact="infection" post="compared to wild-type mice (88). Furthermore, inflammation was shown"/>
  <result pre="prominent antiviral effectors of the innate immune system, and SARS-CoV" exact="infection" post="is highly susceptible to this potent antiviral substance, as"/>
  <result pre="replication and a reduced type I IFN response in SARS-CoV-2" exact="infection" post="of ex-vivo human lung cultures compared to SARS-CoV (104)."/>
  <result pre="T cell responses correlates well with positive outcomes during SARS-CoV" exact="infection" post="(108, 109). Clinical investigations of severe COVID-19 patients consistently"/>
  <result pre="Histological examination of a patient who died from severe SARS-CoV-2" exact="infection" post="identified that whilst the overall peripheral CD4+ and CD8+"/>
  <result pre="for SARS-CoV-2. A considerable number of studies have demonstrated that" exact="infection" post="with SARS-CoV-2 initiates an antibody response. On average, seroconversion"/>
  <result pre="vs. non-critical COVID-19 patients, possibly reflecting more severe and invasive" exact="infection" post="and thus making it difficult to determine the specific"/>
  <result pre="area of investigation. Individuals who recovered from SARS-CoV or MERS-CoV" exact="infection" post="displayed high tires of antibodies which waned after 2â€&quot;3"/>
  <result pre="SARS-recovered individuals identified SARS-specific memory T cells 11 years after" exact="infection" post="(129). Finally, the efficacy and longevity of immunity to"/>
  <result pre="IFN-inducible genes OAS1 and MX1, associated with susceptibility to SARS-CoV" exact="infection" post="and disease progression (134, 135). Moreover, exogenous administration of"/>
  <result pre="suggests that patients with primary T cell defects nor HIV" exact="infection" post="are at a significantly elevated risk. When large cohort"/>
  <result pre="SARS-infected and MERS-CoV-infected patients from previous epidemics were reviewed, HIV" exact="infection" post="was not identified as an independent risk factor for"/>
  <result pre="infection was not identified as an independent risk factor for" exact="infection" post="by these coronaviruses (145, 146). However, evidence for the"/>
  <result pre="However, evidence for the role of T cell defects on" exact="prevalence" post="and severity of COVID-19 is scarce, and it is"/>
  <result pre="patients in Taiwan identified an association between HLA-B*4601 and SARS-CoV" exact="infection" post="(155); however, this was not confirmed in a study"/>
  <result pre="whilst having blood group O was associated with a lower" exact="infection" post="risk. A similar risk pattern for ABO blood groups"/>
  <result pre="role in the natural course of disease and severity during" exact="infection" post="with HCV, it will be interesting to investigate if"/>
  <result pre="how genetic differences may explain the great variability in SARS-CoV-2" exact="infection" post="outcome. As we start to gain further insight into"/>
  <result pre="spectrum, there is the possibility that some individuals may avoid" exact="infection" post="due to protective tissue types or gene mutations. The"/>
  <result pre="restistant to SARS-CoV-2 infection, in analogy to protection from HIV" exact="infection" post="by Delta32 CCR5 homozygosity (166). Given the important role"/>
  <result pre="genetic variants in TMPRSS2 as possible disease modulators of SARS-CoV-2" exact="infection" post="in Italy (168). Although these findings necessitate functional validation,"/>
  <result pre="airway involvement, and interestingly, another study found no difference between" exact="treatment" post="with remdesivir for 5 days compared to 10 days"/>
  <result pre="been demonstrated for the protease inhibitor lopinavir/ritonavir, licensed for HIV" exact="treatment" post="(184, 185), as well as for chloroquine and hydroxychloroquine"/>
  <result pre="well as for chloroquine and hydroxychloroquine presently used in the" exact="treatment" post="of malaria and autoimmune diseases (175, 186, 187). However,"/>
  <result pre="of hydroxychloroquine or chloroquine, with or without a macrolide, for" exact="treatment" post="of COVID-19 comprising data from 671 hospitals in six"/>
  <result pre="(198). Agents which target the host are also potentially valuable" exact="treatment" post="options. Interestingly, the agent camostat mesylate has been reported"/>
  <result pre="the receptor-targeted monoclonal antibodies anakinra and tocilizumab, respectively, in the" exact="treatment" post="of patients with severe COVID-19 in the ICU have"/>
  <result pre="was reported in patients receiving these medications (DMARDs) for the" exact="treatment" post="of rheumatologic conditions (210). On a more hypothetical basis,"/>
  <result pre="the complement system has been suggested as a target for" exact="treatment" post="(211). Finally, numerous ongoing studies are investigating additional novel"/>
  <result pre="healthy, will identify rare, deleterious mutations that lead to SARS-CoV-2" exact="infection" post="and severe clinical outcome. This will offer unique insights"/>
  <result pre="Epstein-Barr virus. Blood. (2014) 123:2148â€&quot;52. 10.1182/blood-2013-11-53868624550228 28.DrutmanSBMansouriDMahdavianiSANeehusALHumDBrykRet al.. Fatal cytomegalovirus" exact="infection" post="in an adult with inherited NOS2 deficiency. N Engl"/>
  <result pre="Sci. (2020) 414:116884. 10.1016/j.jns.2020.11688432464367 42.CheungKSHungIFChanPPLungKCTsoELiuRet al.. Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the hong"/>
  <result pre="10.1128/mBio.00638-1526015500 78.SheahanTMorrisonTEFunkhouserWUematsuSAkiraSBaricRSet al.. MyD88 is required for protection from lethal" exact="infection" post="with a mouse-adapted SARS-CoV. PLoS Pathog. (2008) 4:e1000240. 10.1371/journal.ppat.100024019079579"/>
  <result pre="al.. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med. (2004) 10:290â€&quot;3. 10.1038/nm100114981511 97.SainzBJr.MosselECPetersCJGarryRF. Interferon-beta"/>
  <result pre="106.ZinzulaLTramontanoE. Strategies of highly pathogenic RNA viruses to block dsRNA" exact="detection" post="by RIG-I-like receptors: hide, mask, hit. Antiviral Res. (2013)"/>
  <result pre="Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirus. Clin Microbiol Infect. (2004) 10:1062â€&quot;6. 10.1111/j.1469-0691.2004.01009.x15606632"/>
  <result pre="10.1056/NEJM20030731349052012890855 123.KellamPBarclayW. The dynamics of humoral immune responses following SARS-CoV-2" exact="infection" post="and the potential for reinfection. J Gen Virol. (2020)."/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect Dis."/>
  <result pre="Group. Lancet. (1999) 353:1049â€&quot;53. 10.1016/S0140-6736(98)08350-010199352 142.GarredPMadsenHOBalslevUHofmannBPedersenCGerstoftJet al.. Susceptibility to HIV" exact="infection" post="and progression of AIDS in relation to variant alleles"/>
  <result pre="11:222. 10.1038/s41467-019-13940-631924756 179.de WitEFeldmannFCroninJJordanROkumuraAThomasTet al.. Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection. Proc"/>
  <result pre="trial. Lancet. (2020) 395:1569â€&quot;78. 10.1016/S0140-6736(20)31022-932423584 181.BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACet al.. Remdesivir for the" exact="treatment" post="of Covid-19 - preliminary report. N Engl J Med."/>
  <result pre="N Engl J Med. (2020). 10.1056/NEJMoa2015301 183.AntinoriSCossuMVRidolfoALRechRBonazzettiCPaganiGet al.. Compassionate remdesivir" exact="treatment" post="of severe Covid-19 pneumonia in intensive care unit (ICU)"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 188.CaoBWangYWenDLiuWWangJFanGet al.."/>
  <result pre="N Engl J Med. (2020) 382:2411â€&quot;8. 10.1056/NEJMoa201241032379955 193.RosenbergESDufortEMUdoTWilberschiedLAKumarJTesorieroJet al.Association of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
  <result pre="ahead of print]. 10.1001/jama.2020.8630. 194.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="10.1093/jmcb/mjaa01432236562 196.MehraMRDesaiSSRuschitzkaFPatelANHydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis. Lancet. (2020). 10.1016/S0140-6736(20)31180-6"/>
  <result pre="for a randomized controlled trial on the assessment of camostat" exact="treatment" post="in chronic pancreatitis (TACTIC). Trials. (2019) 20:501. 10.1186/s13063-019-3606-y31412955 202.collab:"/>
  <result pre="https://clinicaltrials.gov/ct2/show/NCT04321096?term=Camostat+mesylate&amp;amp;draw=2&amp;amp;rank=1 (accessed April 16, 2020). 203.ToniatiPPivaSCattaliniMGarrafaERegolaFCastelliFet al.. Tocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
  <result pre="Brescia, Italy. Autoimmun Rev. (2020) 19:102568. 10.1016/j.autrev.2020.102568pagebreak32376398 204.XuXHanMLiTSunWWangDFuBet al.. Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. Proc Natl Acad"/>
 </snippets>
</snippetsTree>
